Legal entity responsible for the study AstraZeneca. Funding AstraZeneca. Disclosure Y. Drew: Advisory / Consultancy, Research grant / Funding (institution): Clovis Oncology; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy: Merck; Advisory / ...
90 or 80 vs. 70). Within each stratum, the patients were randomly assigned (1:1) to receive docetaxel and epirubicin (TE) with or without concurrent lobaplatin (L) treatment. The randomization sequence was generated with Research Randomizer (www.randomizer.org). The study’s statistical team...
The research ethics board at each participating institution approved the protocol and all patients enrolled on study gave written informed consent in accordance with federal and institutional guidelines before treatment. Patients were eligible to enter the study if they had histologically or cytologically ...
MA 02.07 A phase II study of pembrolizumab in EGFR mutant, PD-L1+, tyrosine kinase inhibitor (TKI) naive patients with advanced NSCLC J Thorac Oncol, 12 (11) (2017), p. S1805 View PDFView articleGoogle Scholar 26 E.A. Eisenhauer, P. Therasse, J. Bogaerts, et al. New response eva...
Focusing on international sci-tech frontiers and serving the country's major development demands, the CSNS has supported research in the fields of energy, physics, materials and engineering, such as studies on aerospace components, lithium-ion batteries, solar cell, rare earth magnetism, high-tempera...
Final data available from all high-risk patients enrolled in EPIC-HR study (n= 2,246) confirmed prior results of interim analysis showing PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) reduced risk of hospitalization or death by 89% (within three days of symptom onset...
For translational research, biomarker analyses were performed on formalin-fixed, paraffin-embedded (FFPE) tumor tissue prior to study treatment. PD-L1 expression was assessed by immunohistochemistry (IHC) with the VENTANA™ PD-L1 (SP263) assay (Ventana Medical Systems, Oro Valley, AZ, USA) at...
(CAS), at Week 24. To understand the long-term benefits of TEPEZZA, patients from the Phase 2 clinical trial were followed for 51 weeks (study Week 72) after their last infusion of TEPEZZA. Study findings only include patients who had Week 72 data (n=37). The study...
This phase 2 study evaluated the safety and efficacy of perioperative chemotherapy with S-1 plus oxaliplatin (SOX) for stage III colorectal cancer (CRC). Patients with stage III CRC received surgery after neoadjuvant chemotherapy (NAC; SOX 4 cycles) and
et al. Phase 2 study of oral thalidomide-cyclophosphamide-dexamethasone for recurrent/refractory adult Langerhans cell histiocytosis. Leukemia 36, 1619–1624 (2022). https://doi.org/10.1038/s41375-022-01555-8 Download citation Received19 January 2022 Revised09 March 2022 Accepted21 March 2022 ...